Lonza Group AG, an integrated product and service provider to the biotechnology industry, is expanding its operations in Bend, OR, with a $10 million investment. The expansion includes new suites for developing and manufacturing products. The first suite became operational in December 2020 and the remaining suites will be finished by 2022. Each suite is a space or room designed to provide the appropriate conditions and controls to manufacture a pharmaceutical drug product. The additional suites will allow for the company to expand early-phase work in the pharmaceutical process, such as spray drying, that contributes to greater tablet and capsule production for consumers. The expansion is estimated to result in an additional 35 jobs at the company. Lonza is headquartered in Basel, Switzerland, and has more than 15,000 employees at 120 sites in 35 different countries.